Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nalidixic acid
Drug ID BADD_D01521
Description Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.
Indications and Usage For the treatment of urinary tract infections caused by susceptible gram-negative microorganisms, including the majority of E. Coli, Enterobacter species, Klebsiella species, and Proteus species.
Marketing Status approved; investigational
ATC Code J01MB02
DrugBank ID DB00779
KEGG ID D00183
MeSH ID D009268
PubChem ID 4421
TTD Drug ID D07JGT
NDC Product Code Not Available
UNII 3B91HWA56M
Synonyms Nalidixic Acid | Acid, Nalidixic | Nalidixin | Nalidixate Sodium Anhydrous | Anhydrous, Nalidixate Sodium | Sodium Anhydrous, Nalidixate | Sodium Nalidixic Acid, Anhydrous | Nevigramon | Nalidixate Sodium | Sodium, Nalidixate | Sodium Nalidixic Acid, Monohydrate
Chemical Information
Molecular Formula C12H12N2O3
CAS Registry Number 389-08-2
SMILES CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Asthenia08.01.01.001--Not Available
Blister23.03.01.001; 12.01.06.002--Not Available
Bronchospasm22.03.01.004; 10.01.03.012--
Cholestasis09.01.01.001--Not Available
Chromatopsia06.02.05.001--Not Available
Colour blindness acquired06.02.09.002--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.002--
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.002--Not Available
Disorientation19.13.01.002; 17.02.05.015--Not Available
Disturbance in attention19.21.02.002; 17.03.03.001--
Dizziness17.02.05.003; 02.11.04.006; 24.06.02.007--
Eosinophilia01.02.04.001--
Epilepsy17.12.03.002--Not Available
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Flushing08.01.03.025; 24.03.01.002; 23.06.05.003--
Fontanelle bulging18.04.04.001; 17.02.05.006--Not Available
Gastrointestinal pain07.01.05.005--
Glucose-6-phosphate dehydrogenase deficiency14.14.03.001; 03.08.03.001; 01.06.05.001--Not Available
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.006--
The 1th Page    1 2 3    Next   Last    Total 3 Pages